HRP20120077T1 - Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora - Google Patents

Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora Download PDF

Info

Publication number
HRP20120077T1
HRP20120077T1 HR20120077T HRP20120077T HRP20120077T1 HR P20120077 T1 HRP20120077 T1 HR P20120077T1 HR 20120077 T HR20120077 T HR 20120077T HR P20120077 T HRP20120077 T HR P20120077T HR P20120077 T1 HRP20120077 T1 HR P20120077T1
Authority
HR
Croatia
Prior art keywords
group
substituents
carbon atoms
substituted
independently selected
Prior art date
Application number
HR20120077T
Other languages
English (en)
Croatian (hr)
Inventor
Iguchi Satoru
Katsu Yasuhiro
Sone Hiroki
Uchida Chikara
Kojima Takashi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20120077T1 publication Critical patent/HRP20120077T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Structural Engineering (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20120077T 2003-09-03 2004-08-20 Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora HRP20120077T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50014403P 2003-09-03 2003-09-03
PCT/IB2004/002741 WO2005021539A1 (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-ht4 receptor agonistic activity

Publications (1)

Publication Number Publication Date
HRP20120077T1 true HRP20120077T1 (hr) 2012-02-29

Family

ID=34272920

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120077T HRP20120077T1 (hr) 2003-09-03 2004-08-20 Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora

Country Status (39)

Country Link
US (2) US7776885B2 (sr)
EP (1) EP1664036B1 (sr)
JP (1) JP3983269B1 (sr)
KR (1) KR100738784B1 (sr)
CN (1) CN100482659C (sr)
AP (1) AP2184A (sr)
AR (1) AR045552A1 (sr)
AT (1) ATE539077T1 (sr)
AU (1) AU2004268840B9 (sr)
BR (1) BRPI0414105B8 (sr)
CA (1) CA2537127C (sr)
CR (1) CR8267A (sr)
CY (1) CY1112321T1 (sr)
DK (1) DK1664036T3 (sr)
EA (1) EA009457B1 (sr)
EC (1) ECSP066407A (sr)
ES (1) ES2377484T3 (sr)
GE (1) GEP20084527B (sr)
GT (1) GT200400174A (sr)
HR (1) HRP20120077T1 (sr)
IL (3) IL173705A (sr)
IS (1) IS8289A (sr)
MA (1) MA28021A1 (sr)
MX (1) MXPA06002550A (sr)
NL (1) NL1026959C2 (sr)
NO (1) NO20061519L (sr)
OA (1) OA13248A (sr)
PA (1) PA8610601A1 (sr)
PE (1) PE20050874A1 (sr)
PL (1) PL1664036T3 (sr)
PT (1) PT1664036E (sr)
RS (1) RS20060145A (sr)
SI (1) SI1664036T1 (sr)
TN (1) TNSN06073A1 (sr)
TW (1) TW200510332A (sr)
UA (1) UA86204C2 (sr)
UY (1) UY28496A1 (sr)
WO (1) WO2005021539A1 (sr)
ZA (1) ZA200601324B (sr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
CA2537127C (en) * 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
DE602005016446D1 (de) 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
JP5042028B2 (ja) 2004-11-05 2012-10-03 セラヴァンス, インコーポレーテッド キノリノン−カルボキサミド化合物
KR20070091665A (ko) 2004-12-22 2007-09-11 세라밴스 인코포레이티드 인다졸-카르복사미드 화합물
NZ556627A (en) * 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
WO2006094063A1 (en) 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
DE602006019213D1 (de) 2005-03-15 2011-02-10 Pfizer Benzimidazolonderivate als cb2-rezeptor-liganden
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
ES2359673T3 (es) * 2005-06-07 2011-05-25 Theravance, Inc. Compuestos de benzoimidazolona-carboxamida como agonista del receptor 5-ht4.
ES2391107T3 (es) 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
EP1937670A1 (en) * 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor
EP1943230B1 (en) * 2005-09-30 2010-12-22 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
CA2637275C (en) * 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US20080318964A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched eszopiclone
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055944A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(adhd)의 치료 방법
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP2533780B1 (en) * 2010-02-12 2017-08-23 AskAt Inc. 5-ht4 receptor agonists for the treatment of dementia
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US20120143119A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of Serotonin Receptor Antagonists By Microinjection Systems
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての2,7−ジアザ−スピロ[4,5]デカ−7−イル誘導体のl−リンゴ酸塩およびその結晶形態
US20180344648A1 (en) * 2015-11-30 2018-12-06 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
GEP20257787B (en) * 2020-10-23 2025-08-11 Hk Inno N Corp Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63716A (en) * 1867-04-09 Improved cheery stoner
CH566987A5 (sr) * 1972-04-21 1975-09-30 Ciba Geigy Ag
US3945953A (en) * 1972-04-21 1976-03-23 Ciba-Geigy Corporation ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0522914A1 (fr) * 1991-06-27 1993-01-13 Synthelabo Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5705498A (en) * 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
TW252206B (sr) * 1993-09-01 1995-07-21 Philips Electronics Nv
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6207697B1 (en) * 1997-09-09 2001-03-27 Dupont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6420410B1 (en) * 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
WO2002053568A1 (en) * 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
CA2537127C (en) * 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
AU2005254800B2 (en) * 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
KR100738784B1 (ko) 2007-07-12
ATE539077T1 (de) 2012-01-15
JP3983269B1 (ja) 2007-09-26
PL1664036T3 (pl) 2012-04-30
PE20050874A1 (es) 2005-10-26
UY28496A1 (es) 2005-04-29
ZA200601324B (en) 2007-05-30
GEP20084527B (en) 2008-11-10
CN1845922A (zh) 2006-10-11
UA86204C2 (uk) 2009-04-10
GT200400174A (es) 2005-05-02
IL173705A0 (en) 2006-07-05
CN100482659C (zh) 2009-04-29
PT1664036E (pt) 2012-02-16
EP1664036A1 (en) 2006-06-07
ECSP066407A (es) 2006-09-18
CR8267A (es) 2006-11-21
SI1664036T1 (sl) 2012-03-30
CA2537127C (en) 2011-04-05
MA28021A1 (fr) 2006-07-03
IS8289A (is) 2006-02-09
CY1112321T1 (el) 2015-12-09
NO20061519L (no) 2006-06-01
AU2004268840B9 (en) 2011-02-03
TW200510332A (en) 2005-03-16
BRPI0414105A (pt) 2006-11-21
AP2006003536A0 (en) 2006-04-30
TNSN06073A1 (en) 2007-10-03
ES2377484T3 (es) 2012-03-28
MXPA06002550A (es) 2006-06-20
BRPI0414105B1 (pt) 2018-08-14
IL205600A0 (en) 2010-11-30
NL1026959A1 (nl) 2005-03-07
JP2007533613A (ja) 2007-11-22
HK1093338A1 (zh) 2007-03-02
NL1026959C2 (nl) 2006-01-23
AU2004268840A1 (en) 2005-03-10
EP1664036B1 (en) 2011-12-28
KR20060087540A (ko) 2006-08-02
IL173705A (en) 2013-04-30
US20100273794A1 (en) 2010-10-28
BRPI0414105B8 (pt) 2021-05-25
DK1664036T3 (da) 2012-02-13
AU2004268840B2 (en) 2010-09-23
IL205599A0 (en) 2010-11-30
EA200600327A1 (ru) 2006-08-25
WO2005021539A1 (en) 2005-03-10
PA8610601A1 (es) 2005-03-28
RS20060145A (sr) 2008-06-05
AP2184A (en) 2010-12-02
US20050148573A1 (en) 2005-07-07
AR045552A1 (es) 2005-11-02
OA13248A (en) 2007-01-31
US7776885B2 (en) 2010-08-17
CA2537127A1 (en) 2005-03-10
EA009457B1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
CA2537127A1 (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
US11623921B2 (en) Indole carboxamide compounds
DE69633245T2 (de) Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
JP4394442B2 (ja) 抗炎症剤として有用なスピロ−ヒダントイン化合物
CA2545092A1 (en) Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
CA2569654A1 (en) Benzimidazolone carboxylic acid derivatives
CA2598536A1 (en) Oxyindole derivatives as 5ht4 receptor agonists
CN104203943B (zh) 取代的嘧啶化合物及其作为syk抑制剂的用途
PT1704145E (pt) Inibidores de quinase seletivos
RU2006124518A (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
JP2018522034A (ja) ムスカリン様アゴニスト
JP2012507525A5 (sr)
CA3106470A1 (en) T-type calcium channel blocker
RU2011121665A (ru) Производные 7-гидроксибензимидазол-4-илметанона и содержащие их ингибиторы рвк
CA2615611A1 (en) Indazole derivatives
CA2789663C (en) 5-ht4 receptor agonists for the treatment of dementia
EP2934536B1 (en) FACTOR IXa INHIBITORS
JP2009502770A5 (sr)
CA2598516A1 (en) Benzisoxazole derivatives
AU2016341259B2 (en) Pyridone derivatives and their use as kinase inhibitors
KR20230127271A (ko) 헤테로시클릭 화합물 및 기생충성 질환을 위한 그의용도
CA2421936A1 (en) (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
JPWO2005030722A1 (ja) N−置換−n−(4−ピペリジニル)アミド誘導体
AU2004201666C1 (en) 4-Imidazolin-2-one compounds
TH76314A (th) สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด